AZD3409

AZD3409 is a prenyl inhibitor that exhibits inhibitory activity against both farnesyl transferase and geranylgeranyl transferase I. AZD3409 inhibits the growth of breast cancer cells, with IC50s of 220 nM (MDA-MB-468), 180 nM (MDA-MB-361), and 290 nM (SK-Br-3) . AZD3409 significantly reduces the activation level of AKT in breast cancer cell lines. AZD3409 induces G0/G1 phase arrest in MDA-MB-468 cells, causes G2/M phase arrest in MDA-MB-361 cells. AZD3409 can be used for the study of breast cancer[1].

Product Specifications

CAS Number

[345915-10-8]

Product Name Alternative

EBP-921

UNSPSC

12352005

Target

Akt; Farnesyl Transferase

Related Pathways

Metabolic Enzyme/Protease; PI3K/Akt/mTOR

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

O=C(N[C@@H](CCSC)C(OC(C)C)=O)C1=CC(NC[C@H]2NC[C@H](C2)SC(C3=CN=CC=C3)=O)=CC=C1CCC4=CC=C(F)C=C4

Molecular Formula

C34H41FN4O4S2

Molecular Weight

652.84

References & Citations

[1]Maiello MR, et al. AZD3409 inhibits the growth of breast cancer cells with intrinsic resistance to the EGFR tyrosine kinase inhibitor gefitinib. Breast Cancer Res Treat. 2007 May;102 (3) :275-82.